Gufic BioSciences Stock Screener | Share Price & Fundamental Analysis
GUFICBIO
Pharmaceuticals
Screen Gufic BioSciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹332.65
▼
-4.35 (-1.29%)
Share Price BSE
₹331.95
▼
-6.20 (-1.83%)
Market Cap
₹3,411.11 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
5.40
EPS (TTM)
₹6.95
Dividend Yield
0.03%
Debt to Equity
0.59
52W High
₹484.95
52W Low
₹309.80
Operating Margin
13.00%
Profit Margin
3.90%
Revenue (TTM)
₹205.00
EBITDA
₹27.00
Net Income
₹8.00
Total Assets
₹1,169.00
Total Equity
₹601.00
Gufic BioSciences Share Price History - Stock Screener Chart
Screen GUFICBIO historical share price movements with interactive charts. Analyze price trends and patterns.
Gufic BioSciences Company Profile - Fundamental Screener
Screen Gufic BioSciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GUFICBIO shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE742B01025
Gufic BioSciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GUFICBIO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 |
|---|---|---|
| Assets | ||
| Total Assets | 1,169 | 1,093 |
| Current Assets | 625 | 601 |
| Fixed Assets | 506 | 159 |
| Liabilities | ||
| Total Liabilities | 1,169 | 1,093 |
| Current Liabilities | 181 | 188 |
| Non-Current Liabilities | 0 | 0 |
| Shareholders' Equity | ||
| Total Equity | 601 | 533 |
| Share Capital | 10 | 10 |
| Reserves & Surplus | 591 | 523 |
Screen GUFICBIO income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 205 | 225 | 239 | 196 | 204 | 204 | 210 | 196 | 215 | 202 |
| Expenses | 179 | 190 | 199 | 161 | 167 | 166 | 174 | 159 | 176 | 165 |
| EBITDA | 27 | 34 | 40 | 35 | 37 | 39 | 36 | 36 | 40 | 37 |
| Operating Profit % | 13.00% | 15.00% | 16.00% | 18.00% | 18.00% | 19.00% | 16.00% | 18.00% | 18.00% | 18.00% |
| Depreciation | 8 | 8 | 8 | 4 | 4 | 4 | 5 | 4 | 4 | 4 |
| Interest | 8 | 9 | 10 | 4 | 5 | 5 | 5 | 4 | 5 | 3 |
| Profit Before Tax | 11 | 17 | 23 | 27 | 28 | 29 | 26 | 28 | 31 | 30 |
| Tax | 3 | 4 | 6 | 7 | 7 | 8 | 7 | 7 | 8 | 7 |
| Net Profit | 8 | 13 | 17 | 20 | 21 | 22 | 19 | 21 | 23 | 22 |
| EPS | 0.77 | 1.30 | 1.68 | 2.00 | 2.08 | 2.17 | 1.93 | 2.13 | 2.39 | 2.23 |
Gufic BioSciences Cash Flow Screener - Liquidity Fundamentals
Screen GUFICBIO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March |
|---|---|---|
| Operating Activities | 123 | -8 |
| Investing Activities | -71 | -102 |
| Financing Activities | -37 | 82 |
| Net Cash Flow | 15 | -28 |
Screen GUFICBIO shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 72.51% | 72.51% | 72.50% | 72.51% | 72.51% | 72.51% | 72.51% | 75.00% |
| FII Holding | 0.31% | 0.32% | 0.34% | 0.12% | 0.23% | 0.24% | 0.30% | 0.00% |
| DII Holding | 3.39% | 3.38% | 3.65% | 2.20% | 2.39% | 2.51% | 2.98% | 1.16% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 15.15% | 15.10% | 14.45% | 16.72% | 16.36% | 16.01% | 15.44% | 17.83% |
| Other Holding | 8.64% | 8.70% | 9.06% | 8.45% | 8.52% | 8.73% | 8.76% | 6.01% |
| Shareholder Count | 31,844 | 31,876 | 31,420 | 34,695 | 32,250 | 32,825 | 33,299 | 38,902 |
Gufic BioSciences Dividend Screener - Share Yield Analysis
Screen GUFICBIO dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.10 | 0.03% |
| 2024-March | ₹0.10 | 0.03% |
| 2023-March | ₹0.10 | 0.04% |
| 2022-March | ₹0.10 | 0.05% |
| 2021-March | ₹0.10 | 0.04% |
| 2020-March | ₹0.05 | 0.04% |
| 2019-March | ₹0.05 | 0.10% |
| 2018-March | ₹0.05 | 0.07% |
| 2017-March | ₹0.05 | 0.05% |
Gufic BioSciences Index Membership - Market Screener Classification
Screen GUFICBIO by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Gufic BioSciences Market Events Screener - Corporate Actions
Screen GUFICBIO market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.10 /share | -5.49% | ||
| Dividend | ₹ 0.10 /share | 4.55% | ||
| Dividend | ₹ 0.10 /share | 37.48% | ||
| Annual General Meeting | NA | -7.11% | ||
| Dividend | ₹ 0.10 /share | 27.37% | ||
| Annual General Meeting | NA | -0.95% | ||
| Annual General Meeting | NA | -3.20% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | -0.69% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | -2.72% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | 2.75% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -4.73% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -7.61% |
| 2022-08-24 | 2022-08-25 | Dividend | ₹ 0.10 /share | -15.82% |
Gufic BioSciences Competitors Screener - Peer Comparison
Screen GUFICBIO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 413,429 | 39.37 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,971 | 67.76 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 131,280 | 60.85 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,626 | 22.30 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 104,220 | 18.24 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 95,841 | 22.10 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,005 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 90,565 | 50.34 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 70,138 | 20.25 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 66,209 | 27.11 | 13,458 | 3.70% | 2,216 | 38.49 |
Gufic BioSciences Company Announcements - News Screener
Screen GUFICBIO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-04 | Closure of Trading Window | View |
| 2026-01-01 | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-12-10 | Intimation Of Environmental Social And Governance (ESG) Rating | View |
| 2025-11-21 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-21 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-14 | Results - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-14 | Board Meeting Outcome for Meeting Held On Friday November 14 2025 | View |
| 2025-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-11-07 | Board Meeting Intimation for Consideration And Approval Of Inter Alia Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-29 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |